These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29728450)

  • 1. Constellation of autoimmune manifestations in a patient with Graves' disease.
    Dutta A; Jain N; Bhansali A
    Postgrad Med J; 2018 Sep; 94(1115):538. PubMed ID: 29728450
    [No Abstract]   [Full Text] [Related]  

  • 2. IgG, IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves' disease: their in vitro solubilization by intravenous immunoglobulin.
    Antonelli A; Palla R; Casarosa L; Fallahi P; Baschieri L
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S31-5. PubMed ID: 8828945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Severe Graves' acropachy and dermopathy. Three case reports].
    Proust-Lemoine E; Vantyghem MC; Bauters C; Nocaudie M; Wémeau JL
    Presse Med; 2005 Mar; 34(5):367-70. PubMed ID: 15859571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of tissue specific and tissue non specific autoimmune reactions of Graves' disease.
    Kiljanski J; Nebes V; Wall JR
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S69-76. PubMed ID: 8828951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin A class fibroblast antibodies in patients with Graves' disease and pretibial myxedema.
    Arnold K; Metcalfe R; Weetman AP
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3430-7. PubMed ID: 8530579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy.
    Fatourechi V; Bartley GB; Eghbali-Fatourechi GZ; Powell CC; Ahmed DD; Garrity JA
    Thyroid; 2003 Dec; 13(12):1141-4. PubMed ID: 14751035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Puzzles in practice. Case report. A 62-year-old black woman with known Graves' disease. Diagnosis: Graves' dermopathy (elephantiasic type) and Graves' acropachy.
    Mishriki YY
    Postgrad Med; 2010 Mar; 122(2):162-4. PubMed ID: 20203468
    [No Abstract]   [Full Text] [Related]  

  • 8. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
    Molnár I; Bokk A
    Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.
    Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L
    Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' disease and Graves' orbitopathy following COVID-19.
    Lanzolla G; Marcocci C; Marinò M
    J Endocrinol Invest; 2021 Sep; 44(9):2011-2012. PubMed ID: 33964007
    [No Abstract]   [Full Text] [Related]  

  • 11. Concomitant Graves' disease and Hashimoto's thyroiditis, presenting as primary hypothyroidism.
    Cronin CC; Higgins TM; Murphy D; Ferriss JB
    Ir Med J; 1996; 89(4):141-2. PubMed ID: 8824038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of high-dose intravenous immunoglobulin treatment of patients with pretibial myxedema and Basedow's disease. Preliminary findings].
    Antonelli A; Saracino A; Agostini S; Alberti B; Melosi A; Gambuzza C; Avantaggiato G; Baschieri L
    Clin Ter; 1992 Sep; 141(9 Pt 2):63-8. PubMed ID: 1281765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A rare hyperthyroid syndrome].
    Artuso V; Roiter I
    Minerva Endocrinol; 2004 Jun; 29(2):71-5. PubMed ID: 15257258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.
    Gopinath B; Musselman R; Adams CL; Tani J; Beard N; Wall JR
    Thyroid; 2006 Oct; 16(10):967-74. PubMed ID: 17042681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretibial myxedema without ophthalmopathy: an initial presentation of Graves' disease.
    Lohiya S; Lohiya V; Stahl EJ
    Am J Med Sci; 2013 Jul; 346(1):73-5. PubMed ID: 23514670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretibial myxedema: pathophysiology and treatment options.
    Fatourechi V
    Am J Clin Dermatol; 2005; 6(5):295-309. PubMed ID: 16252929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto's who developed Graves' disease and pretibial myxoedema.
    Kamath C; Young S; Kabelis K; Sanders J; Adlan MA; Furmaniak J; Rees Smith B; Premawardhana LD
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):465-70. PubMed ID: 22891608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of Graves' ophthalmopathy.
    Gorman CA; Bahn RS
    Dev Ophthalmol; 1989; 20():1-7. PubMed ID: 2687045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.